Literature DB >> 9559829

In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections.

H M Wexler1, E Molitoris, D Molitoris, S M Finegold.   

Abstract

The in vitro activity of levofloxacin was compared to the activities of ofloxacin, ciprofloxacin, ampicillin-sulbactam (2:1), cefoxitin, and metronidazole for a selected group of anaerobes (n = 175) isolated from skin and soft tissue infections by using the National Committee for Clinical Laboratory Standards-approved Wadsworth method. Ampicillin-sulbactam and cefoxitin inhibited 99% of the strains of this select group, levofloxacin and ofloxacin inhibited 73 and 50%, respectively, at 2 microg/ml, and ciprofloxacin inhibited 51% at 1 microg/ml. The geometric mean MIC of levofloxacin was lower than those of ofloxacin and ciprofloxacin for every group except Veillonella.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9559829      PMCID: PMC105588          DOI: 10.1128/AAC.42.4.984

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Comparative activity of ciprofloxacin against anaerobic bacteria.

Authors:  V L Sutter; Y Y Kwok; J Bulkacz
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

2.  Oral levofloxacin 600 mg and 300 mg daily doses in difficult-to-treat respiratory infections.

Authors:  H Shishido; K Furukawa; H Nagai; K Kawakami; H Kono
Journal:  Drugs       Date:  1995       Impact factor: 9.546

3.  In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria.

Authors:  P B Fernandes; N Shipkowitz; R R Bower; K P Jarvis; J Weisz; D T Chu
Journal:  J Antimicrob Chemother       Date:  1986-12       Impact factor: 5.790

4.  Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

5.  The comparative in-vitro activity of eight newer quinolones and nalidixic acid.

Authors:  A King; I Phillips
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

6.  Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections.

Authors:  B M Jones; I Geary; M E Lee; B I Duerden
Journal:  J Antimicrob Chemother       Date:  1986-06       Impact factor: 5.790

Review 7.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.

Authors:  R Davis; H M Bryson
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

8.  In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.

Authors:  K P Fu; S C Lafredo; B Foleno; D M Isaacson; J F Barrett; A J Tobia; M E Rosenthale
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

9.  Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates.

Authors:  E J Goldstein; C A Nesbit; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

10.  Is ciprofloxacin active against clinically important anaerobes?

Authors:  B Watt; F V Brown
Journal:  J Antimicrob Chemother       Date:  1986-05       Impact factor: 5.790

View more
  9 in total

1.  Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model.

Authors:  Liqin Zhu; Yuan Zhang; Jianwei Yang; Yongming Wang; Jianlei Zhang; Yuanyuan Zhao; Weilin Dong
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-03-10       Impact factor: 2.441

Review 2.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

4.  Transposon mutagenesis of the anaerobic commensal, Bacteroides fragilis, using the EZ::TN5 transposome.

Authors:  Yaligara Veeranagouda; Fasahath Husain; Hannah M Wexler
Journal:  FEMS Microbiol Lett       Date:  2012-06-18       Impact factor: 2.742

Review 5.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Levofloxacin: an updated review of its use in the treatment of bacterial infections.

Authors:  Miriam Hurst; Harriet M Lamb; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Bacteroides: the good, the bad, and the nitty-gritty.

Authors:  Hannah M Wexler
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

8.  Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients.

Authors:  Amparo Sánchez Navarro; Clara-Isabel Colino Gandarillas; Francisco Alvarez Lerma; Y Alcalde Menacho; Alfonso Domínguez-Gil
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

9.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.